ReviewOncology research2025
Reprogramming the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: Therapeutic Targets and Innovations.
Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Radiotherapy-Associated Pain in Head and Neck Cancer: From Clinical Burden to Neuroimmune Modulator.Journal of clinical medicine · 2026Review
- Metabolism and Metabolic Reprogramming in Laryngeal Squamous Cell Carcinoma.Biomedicines · 2026Review
- Design of a Predictive Recurrence Scoring System in Oral Squamous Cell Carcinoma.Journal of clinical medicine · 2026Review
- A preliminary exploration of the role and mechanisms of CD93 in promoting the malignant progression of head and neck squamous cell carcinoma.Frontiers in pharmacology · 2026Article
- Mechanistic insights into the role of oral microbiome in the malignant transformation of oral lichen planus to oral squamous cell carcinoma.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with high recurrence rates and prevalent resistance to therapeutic interventions. Tumor behavior is largely dependent on the tumor microenvironment (TME) that includes immune cells, stromal components, cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM), and an associated cytokine network. In this review, we examine principal mechanisms of the tumorigenic transformation, encompassing immune checkpoint disruption, therapy resistance mediated through CAFs, the contribution of hypoxic niches, and several metabolic dependencies that hold potential as future targets. Novel therapeutics developed and/or repurposed, such as immune checkpoint inhibitors (ICIs), TME modulation therapeutics, CAF reprogramming, hypoxia targeting agents, and ECM remodeling, aim to overcome TME-mediated resistance. We also examine the rationale and progress of integrating TME-targeted therapies with other treatment modalities. By identifying actionable, molecular targets within the HNSCC TME, this review presents a translational perspective for implementing TME modulation in personalized treatment. The challenges comprise TME heterogeneity, a paucity of predictive biomarkers, and a translational gap between pre-clinical and clinical practice. Future studies must be aimed at proper stratification of patients, optimization of combination treatment, and cost-effectiveness analysis of TME-modifying therapies to enable personalized medicine in HNSCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.